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ABSTRACT 
ESBL-producing Enterobacteriaceae (EPE) has become a major cause of community 
acquired urinary tract infection (UTI), and fecal carriage of EPE is emerging 
worldwide. The aims of this thesis were to study the molecular epidemiology of 
ESBL-enzymes in Stockholm (I) to evaluate treatment alternatives to the 
carbapenems for EPE (I-III), and to study the duration of fecal carriage and identify 
factors associated with prolonged carriage (IV). 
 Paper I describes a consecutive collection of EPE (n=169). The distribution of 
ESBL-enzymes and clonal relatedness of the isolates was determined with PCR, 
DNA sequencing and pulsed-field gel electrophoresis (PFGE). Antimicrobial activity 
was evaluated using gradient test, broth microdilution and disk diffusion, and the 
susceptibility test methods were compared for parenteral !-lactams. We found that 
CTX-M-15 (75%) and CTX-M-14 (23%) were the dominating genotypes, that the 
collection was largely polyclonal and that 41% of E. coli belonged to the international 
clone sequence type (ST) 131. We concluded that there are several oral (mecillinam, 
nitrofurantoin, fosfomycin) and parenteral (piperacillin-tazobactam, tigecycline, 
temocillin) treatment alternatives for E. coli but few for K. pneumoniae. We also 
showed that susceptibility rates obtained with Etest and disk diffusion (DD) were not 
in agreement with the reference method broth microdilution for piperacillin-
tazobactam (TZP). Etest and DD are therefore not reliable to detect resistance to TZP, 
with the breakpoints used at the time of the study.  
 In paper II the novel cephalosporin CXA-101 (later known as ceftolozane) in 
combination with tazobactam (CXA-201) was evaluated against the same collection 
of isolates as in paper I, and compared to other !-lactam/!-lactamase inhibitors. 
MICs were determined with broth microdilution and susceptibility to CXA-201 was 
88-98%, depending on the concentration of tazobactam and the tentative breakpoint 
used. All ACL-resistant and 94% of the TZP-resistant isolates were CXA-201 
susceptible. We concluded that ceftolozane-tazobactam (CXA-201) is a potential 
future therapeutic option against EPE, especially for TZP-resistant isolates. 
 Paper III evaluates the clinical and bacteriological activity of pivmecillinam 
for patients treated for lower UTI caused by an EPE (n=8). The clinical cure (resolved 
UTI symptoms after completed treatment) was high (8/8) but bacteriological cure (< 
10
3
 CFU/ml at follow-up after 30 days) was low (2/8), although none of the patients 
with persisting bacteriuria relapsed within 6 months.  
          In paper IV we studied the duration and dynamics of ESBL-carriage. A cohort 
of patients (n=61) were followed with fecal samples and questionnaires about 
antimicrobial treatment and risk factors for EPE, 1, 3, 6 and 12 months after EPE 
infection. EPE strains were subjected to PFGE, PCR for phylogrouping, detection of 
CTX-M phylogroup, pabB (ST131) and virulence genes and PCR based replicon 
typing. Patient and strain related variables were compared for carriers and non-carriers 
at 12 months. We concluded that EPE carriage is common 12 months after infection 
(43%) and that persisting carriage may be associated with E. coli phylogroup B2 and 
CTX-M-9. The strain background frequently changes throughout the carriage and 
negative samples do not imply eliminated carriage. 
           This knowledge will hopefully contribute to providing better medical care of 
patients with infection caused by EPE. It may also prove important for defining patients 
in require of prolonged isolation in single rooms or cohorts. Thereby the spread of EPE 
in hospitals and long term care facilities can be limited. 
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1 INTRODUCTION 
The discovery of antimicrobial agents was one of the greatest medical breakthroughs 
of the 20th century that revolutionized the treatment of bacterial infections. 
Unfortunately the widespread use and misuse of antibiotics have resulted in a gradual 
emergence of antimicrobial-resistant bacteria, and multiresistance in various species 
has become a major threat. In the 21st century there has been an alarming trend with 
increasing multiresistance among bacteria belonging to the Enterobacteriaceae. The 
Enterobacteriaceae is a large family of Gram-negative, rod-shaped, non-fermenting 
facultative anaerobe bacteria. Most Enterobacteriaceae are members of the normal 
intestinal flora of humans and animals, others are found in water or soil. However, the 
group also includes common human pathogens, of which Escherichia coli and 
Klebsiella pneumoniae are considered the most important (Mandell 2000, Schaechter 
1993). E. coli and K. pneumoniae cause various types of infections, including urinary 
tract infection (UTI), bloodstream infection (BSI) and severe hospital-acquired 
infections. UTI is the most common type of infection, with E. coli accounting for 70–
95% of the community onset and approximately 50% of the nosocomial cases. 
Around 20% of adult women suffer from at least one UTI in their lifetime, and 
recurrent or relapsing UTIs are problematic in many individuals (Foxman 2010). 
Hence, widespread multiresistance among E. coli will have major implications.   
 
Infections caused by E. coli and K. pneumoniae are normally treated with !-lactam 
antibiotics. The !-lactams is a broad class of antimicrobials that contain a four-atom 
ring (!-lactam ring) in their molecular structure. They work by inhibiting cell wall 
synthesis in the bacterial organism. The group includes the penicillins, cephalosporins 
e.g. cefotaxime, ceftriaxone and ceftazidime, monobactams and carbapenems. 
Resistance among E. coli and K. pneumoniae is most often due to inactivation of these 
antibiotics by enzymes through hydrolysis of the !-lactam ring (Fig. 1), so called 
extended-spectrum !-lactamases (ESBLs). ESBLs are able to break down penicillins, 
cephalosporins, monobactams and sometimes carbapenems (Giske et al. 2009).  
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Figure 1. Inactivation of a cephalosporin through hydrolysis of the !-lactam ring by an 
ESBL 
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Infections caused by ESBL-producing Enterobacteriaceae (EPE) are not more severe 
than similar infections caused by non-ESBL-producing strains. However, because the 
ESBL inactivates the most commonly used antimicrobial agents, empirical treatment is 
often ineffective and adequate treatment delayed. Therefore, infections with EPE are 
associated with increased mortality, length of hospital stay and health care costs (Giske 
et al. 2008, Rottier et al. 2012).  
 
ESBL genes are transferable between bacteria by horizontal gene transfer through 
plasmids. A plasmid is a double-stranded, extra-chromosomal mobile genetic element 
that replicate independently of the chromosome. Plasmids carry genes non-essential for 
bacterial survival although they provide benefits to the bacterium by encoding genes for 
virulence, environmental adaptability and persistence, metabolic functions and 
resistance to heavy metals and antibiotics.  
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Figure 2. Schematic structure of a plasmid 
 
Plasmids replicate independently of the chromosome and partition themselves between 
daughter cells after cell division. Some plasmids are also able to transfer themselves to 
other bacteria through bacterial conjugation. The principles of conjugation are shown in 
Fig. 3.  
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Figure 3. Principles of bacterial conjugation 
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Plasmids vary in size and carry between one and over one thousand genes. Larger 
plasmids are present in smaller numbers (1-2) and small plasmids may be found in high 
copy numbers (~40). Plasmids that are closely related and share common replication 
control systems cannot be propagated stably in the same cell line; hence, they are 
incompatible and classified into the same incompatibility group (Inc) (Datta and 
Hedges 1971). There are >30 Inc groups described, and major groups occurring in 
Enterobacteriaceae are HI2, HI1, I1-!, X, L/M, N, FIA, FIB, FIC, W, Y, P, A/C, T, K, 
B/O, FII, FIII, FIV. ESBL-genes are often found on IncF, I and N plasmids (Carattoli 
2013). IncF plasmids are large low-copy-number plasmids that often carry more than 
one replicon. These plasmids often also harbour other resistance genes. Therefore, 
ESBL-producing bacteria are not only resistant to !-lactams but frequently also to other 
groups of antibiotics including aminoglycosides, quinolones and trimethoprim-
sulfamethoxazole (Paterson and Bonomo 2005, Pitout 2012).  
 
There is a large number of ESBL-variants, and new enzymes are frequently being 
detected. In 2009 the definition of ESBL was broadened and now includes three classes 
of !-lactamases (ESBLA, ESBLM, and ESBLCARBA) (Giske et al. 2009) shown in Table 
1. However, in the literature, ESBL most often refers to the “classical” and most 
common ESBLs, ESBLA, which includes the dominating CTX-M-enzymes. ESBLM 
shares phenotype with ESBLA but is less frequent and not so well studied. ESBLCARBA 
is resistant also to the carbapenems and is therefore an even greater challenge for health 
care, although still very rare in Sweden. In this thesis ESBL refers to ESBLA.  
 
 Table 1. Classification of ESBL enzymes 
Class of 
ESBL 
Ambler 
class 
Enzymes Inhibited by 
ESBLA A CTX-M, TEM/SHV-ESBL Clavulanic 
acid 
ESBLM C Plasmid AmpC Cloxacillin 
A KPC Boronic acid 
B Metallo-!-lactamases (VIM, NDM, 
IMP) 
EDTA 
ESBLCARBA 
D OXA-48 No inhibitor* 
 
*Inhibited by the new !-lactamase-inhibitor avibactam, no commercial assays available 
yet. Resistant to temocillin (www.nordicast.org). 
 
The past decade the CTX-M-enzymes have emerged globally and ESBL has gone from 
being a rare problem associated with K. pneumoniae hospital-acquired infections, to a 
major cause of community-acquired E. coli UTI. Asymptomatic fecal carriage of EPE 
among healthy individuals has become endemic in many countries and is spreading 
rapidly throughout the world through food and water resources, with the help from 
travellers. When this project was initiated in 2006, an increase in EPE had been noted 
also in Sweden. Data on their local molecular epidemiology was non-existing and 
needed to be addressed. Today EPE is a clinical problem that physicians deal with on 
an everyday basis. Therapeutic options for infections caused by EPE are few, and 
primary care patients with UTI are frequently admitted for intravenous carbapenem 
treatment. The broad-spectrum carbapenems are considered the drugs of choice, but are 
not suited for treatment of non-severe infections. Apart from being inconvenient and 
  4 
expensive, the increasing use of the carbapenems contributes to the selection of 
resistant strains in the gut (Falagas 2012), and has led to an alarming rise in 
carbapenem resistance in many countries (Nordmann et al. 2009). The use of 
carbapenems must be reduced, but what are the alternatives? Data on the activity of 
other agents against EPE is limited, and old as well as novel agents, need to be 
evaluated against ESBL-producing isolates (Talbot et al. 2006).  
Along with the increasing detection of EPE, the prevalence and risk factors for fecal 
carriage have been described. However, little is known about the time course and 
dynamics of stool colonization of EPE. The lack of knowledge constitutes a problem 
not only from an infection control perspective, but also poses a problem to clinicians 
having to inform patients about the finding of EPE in clinical or screening samples. 
How long does one carry the bacteria? Can they be eliminated? Which patients are at 
risk for prolonged carriage? How long do we need to consider these bacteria as 
potential pathogens and what patients require cohorting and isolation upon readmission 
to prevent the spread to others within the hospital? These are important and frequently 
asked questions that cannot be answered without increased knowledge on the duration 
of fecal carriage of ESBL.  
 
The aims of the research presented in papers I-IV were to study the epidemiology of 
ESBLs in Stockholm (I), to evaluate existing and new treatment alternatives to the 
carbapenems (I-III), and to study the duration and dynamics of fecal carriage of EPE 
(IV). This was carried out through molecular investigations of a consecutive collection 
of EPE from Stockholm (I, II), and by following a cohort of patients after clinical 
infection caused by EPE (III, IV).  
 
In the following sections I present and discuss findings from paper I-IV while placing 
them in a wider context. I begin by introducing the most common type of ESBL, the 
CTX-M-enzymes, and describe their clinical dissemination and molecular 
epidemiology, globally and in Stockholm (I). I then proceed to discussing treatment 
alternatives to the carbapenems, while highlighting some of the findings from paper I-
III. I end with a section on fecal carriage, with special emphasis on duration of carriage 
and host and pathogen factors possibly affecting it (IV). Details on materials, methods, 
results and discussion can be found in the papers and will not be repeated unless it is 
relevant for the understanding. ESBLs constitute an extensive field of research, and my 
intention is not to present a voluminous review, but to give an understanding of the 
work presented in the papers.  
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2 CLINICAL DISSEMINATION AND MOLECULAR 
EPIDEMIOLOGY OF EPE 
2.1 THE CTX-M-ENZYMES 
The first ESBL was described in 1983 (Knothe et al. 1983). Until the end of the 1990s 
the majority of the ESBL-enzymes reported were of the TEM- (Temoneira, named after 
a patient) or SHV- (Sulf-hydryl variable) types. These enzymes had evolved from the 
previously known penicillinases TEM-1 and 2 and SHV-1 by point mutations, and 
were mostly produced by nosocomial bacteria, especially Klebsiella spp, and found in 
patients with severe hospital-acquired infections. Risk factors for acquisition were long 
term hospital stays, especially in the intensive care unit, intubation, catheterization and 
previous exposure to antimicrobials. The spread was clonal, and many cases were 
related to outbreaks in hospital wards (Paterson and Bonomo 2005).   
 
In 1986 a new type of ESBL was found in the feces of a Japanese dog. This enzyme 
had an elevated activity against cefotaxime and was therefore named CTX-M 
(CefoTaXimase, first isolated in Munich) after being isolated in Germany in 1989 
(Bauernfeind et al. 1990). Originally, the CTX-M genes were picked up from the 
chromosomes of the environmental bacteria Kluyvera spp by mobile genetic elements, 
and had continued to spread to other species through bacterial conjugation of plasmids. 
Since 2000 the CTX-M enzymes have emerged globally (Canton and Coque 2006), and 
in a multinational study from 2009, CTX-M enzymes accounted for 65% of all !-
lactamases (Ben-Ami et al. 2009). While SHV and TEM are mostly limited to 
nosocomial outbreaks, the CTX-M enzymes are widely spread in the community. CTX-
M-producing Enterobacteriaceae has become an important cause of community onset 
UTI (Pitout and Laupland 2008). 
 
There is a large number of CTX-M variants, and novel enzymes are frequently being 
described, reflecting their rapid spread and evolution. There are currently >100 
different CTX-M-enzymes, divided into six groups (1, 2, 8, 9, 25 and 45), based on 
their amino-acid sequences (Bonnet 2004, Rossolini et al. 2008). CTX-M-15, which 
belongs to the CTX-M-1-group, is the most widely spread enzyme internationally( 
Oteo et al. 2010) and in Sweden (I). CTX-M-15 is not only the most common ESBL-
enzyme, it is also associated with the most multi-resistant phenotype (Pitout 2012, I). 
The highly resistant profile often described with E. coli producing CTX-M-15 may be 
explained by the association of CTX-M-15 with the co-production of other !-
lactamases (TEM-1, OXA-1) and the aminoglycoside-modifying enzyme Aac(6’)-Ib-
CR. Aac(6’)-Ib-CR not only accounts for aminoglycoside-resistance but can also 
cause flouroquinolone-resistance through acetylation. The production of CTX-M-15, 
TEM-1, OXA-1 and Aac(6’)-Ib-CR has been linked to epidemic IncFII plasmids 
(Peirano and Pitout 2010). 
 
 
2.1.1 CTX-M-15 and the international E. coli clone ST131 
The high spreading capacity of CTX-M-15- producing E. coli could be explained by 
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the horizontal gene transfer through plasmids harbouring blaCTX-M-15, or by the spread 
of an epidemic clone with selective advantages. The literature supports that the 
international dissemination of CTX-M-15 is at least in part due to the rapid spread of 
the international E. coli clone sequence type 131 (ST131) identified through multilocus 
sequence typing (MLST) (Oteo et al. 2010). ST 131 is a gut colonizer and uropathogen, 
belonging to the most virulent E. coli phylogroup B2 (serotype 025b-H4). It has 
acquired the IncFII-plasmid containing the CTX-M-15, TEM-1, OXA-1, aac(6’)-Ib-cr 
complex, and by this gained the selective advantage of multiple antimicrobial 
resistance genes in addition to its enhanced virulence factors (Pitout). This 
unfortunate combination has led to the spread of CTX-M-15 between hospitals, long-
term care facilities and, not the least, in the community. ST131 is believed to have 
spread through food and contaminated water resources and ESBL, including CTX-M-
15 and other CTX-M-types belonging to ST131, have been found in farm animals, 
food, sewage, rivers and lakes (Mesa et al. 2006). Several studies indicate that 
travellers help transporting the bacteria between countries and continents (Tangden et 
al. 2010, van der Bij and Pitout 2012). Fecal carriage of ESBL has also been reported 
to be widespread among wild populations including migrating birds (Guenther et al. 
2012). Wildlife may serve as an environmental reservoir for ESBL and humans may 
be re-infected through contact with the animals’ feces. Bird migration could therefore 
contribute to the global dissemination of ESBL, in similar ways that have been 
described for human travel.  
 
 
2.2 GLOBAL DISSEMINATION OF CTX-M-ENZYMES AND ST131 
The proportion of ESBL-producing E. coli and K. pneumoniae varies geographically (3 
to 80%). The highest prevalences are reported from Asia, Latin America and some 
European countries(Oteo et al. 2010). In the Asia-Pacific region and in Latin America 
40% and 30% respectively of E. coli and Klebsiella spp. from patients with intra-
abdominal infections have been reported ESBL-positive. In India as many as 79% of 
clinical isolates of E. coli have been found to be ESBL-producing. In China and 
Thailand the published numbers are around 50% (Hawser et al. 2009). In Europe the 
highest rates are found in the southern and eastern parts (10 to 25%), as displayed in 
Fig. 4, which shows the percentage of invasive E. coli isolates with resistance to third-
generation cephalosporins by country in 2011. However, it should be noted that some 
countries do not have the routine to report all isolates, which may lead to an 
overestimate of the proportion of ESBL-producing isolates. 
Specific CTX-M genotypes are associated with different geographical regions. CTX-
M-15 is the most widely spread genotype followed by CTX-M-14 and CTX-M-3. 
CTX-M-14 and CTX-M-3 are common in China, Japan, South East Asia and North 
America. CTX-M-2 dominates in South America (Hawkey and Jones 2009). In 
Europe, the majority of the enzymes belong to the CTX-M-1-group (CTX-M-3 and -
15) and the CTX-M-9-group (CTX-M-9 and -14) (Oteo et al. 2010). In India, with its 
large population and extremely high frequency of EPE, no other genotype than CTX-
M-15 has been described. Also in regions with a tradition of other dominating 
enzymes, like China and the USA, CTX-M-15 is catching up and replacing the other 
enzymes (Hawkey and Jones 2009). In reports from the USA as well as from Canada, 
Norway and Spain, the majority of the CTX-M-15 isolates have been related to ST131 
(Nicolas-Chanoine et al. 2008, Peirano and Pitout 2010). 
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4.1 Escherichia coli
4.1.1 Clinical and epidemiological importance
Escherichia coli is the gram-negative rod most fre-
quently isolated from blood cultures. It is the most 
frequent cause of bacteraemia, community- and hospi-
tal-acquired urinary tract infections, is associated with 
spontaneous and post-surgical peritonitis and with skin 
and soft tissue infections of polymicrobial aetiology, 
causes neonatal meningitis and is one of the leading 
causative agents in food-borne infections worldwide.
4.1.2 Resistance mechanisms
In E. coli, resistance to beta-lactams is mostly due to 
production of beta-lactamases, which hydrolyse the 
beta-lactam ring of beta-lactam antimicrobials, which 
is crucial for inhibition of the penicillin-binding protein 
(PBP) targets. Resistance to broad-spectrum penicillins, 
such as ampicillin or amoxicillin, is usually conferred by 
plasmid coded beta-lactamases mainly of the TEM type 
and to a lesser extent of the SHV type, (whereby TEM-1 
accounts for up to 60% of aminopenicillin resistance), 
while resistance to third-generation cephalosporins 
is mostly conferred by extended-spectrum beta-lacta-
mases (ESBLs). The first ESBLs spreading in E. coli were 
variants of the TEM or SHV enzymes in which single or 
multiple aminoacid substitutions expand their hydrolys-
ing ability to include third-generation cephalosporins 
(in this report referring to cefotaxime, ceftriaxone and 
ceftazidime), fourth-generation cephalosporins and 
monobactams. During the past decade, however, these 
enzymes have largely been replaced by the CTX-M-type 
ESBLs, which are now the most common ESBLs in E. coli. 
Most ESBLs can be inhibited by beta-lactamase inhibi-
tors such as clavulanic acid, sulbactam or tazobactam. 
More than 250 ESBL variants are known to date. An 
important factor in their global dominance is the wide 
dissemination of particular plasmids or bacterial clones 
producing CTX-M-type ESBLs (e.g. CTX-M-15). Other 
enzymes affecting the susceptibility to third-genera-
tion cephalosporins include plasmid-encoded variants 
derived from some chromosomal AmpC-type beta-lacta-
mases. CMY-2 is the most widespread enzyme belonging 
to this group, which is still less common than ESBLs in E. 
coli in Europe, but frequently seen in the United States. 
An important threat that will require close surveillance 
in the future is the emergence of carbapenem resistance 
in E. coli, mediated by metallo-beta-lactamases (such as 
the VIM or IMP enzymes, or the emerging NDM enzyme) 
or serine-carbapenemases (such as the KPC enzymes), 
providing resistance to most or all available beta-lactam 
4 Antimicrobial resistance in Europe
Figure 4.1: Escherichia coli: percentage (%) of invasive isolates with resistance to third-generation cephalosporins by 
country, EU/EEA countries, 2011 
Liechtenstein
Luxembourg
Malta
Non-visible countries
10% to < 25%
25% to < 50%
≥ 50% 
No data reported or less than 10 isolates
Not included
< 1%
1% to < 5%
5% to < 10%
 
Figure 4. Percentage (%) of invasive isolates with resistance to third-generation 
cephalosporins by country, EU/EEA countries, 2011 (EARS-Net database 2011).  
 
 
2.2.1 CTX-M-enzymes and ST131 in Sweden  
When this work was initiated in 2006, there was no data on the prevalence of ESBLs in 
Sweden. Mandatory laboratory reporting was introduced in 2007, and has shown that 
EPE is by far the most common and fastest increasing type of multiresistance in the 
country, with 7,225 reported cases during 2012 and 1,880 cases in Stockholm (Fig. 5).  
 
 
Figure 5. Notifiable resistance in Stockholm 2006-2012 (The Swedish Institute for 
Communicable Disease Control (www.smittskyddsinstitutet.se)). 
 
The proportion of cephalosporin-resistant isolates in blood is now (2011) around 3% in 
the country (Fig. 4). According to the SWEDRES-report from the same year, which 
presents data on a national level from the Swedish surveillance of antibiotic resistance 
  8 
programme, the most commonly reported species with ESBL was E. coli, accounting 
for 87% of all cases, followed by K. pneumoniae with 7% and Proteus mirabilis 
(0.5%). In 63% of the cases the EPE was detected in a urine sample, and 22% in fecal 
samples or rectal swabs. In additional genotypic analyses of 508 cefadroxile-resistant 
urine isolates collected from all clinical microbiology laboratories in Sweden during 
one month in 2011, 82% were ESBL-producers. Of these, 93.3% had ESBLA, 6.3% 
ESBLM, and 0.5% both ESBLA and ESBLM. Among the ESBLA, CTX-M belonging 
to group 1 was the most prevalent enzyme (73.5%), followed by CTX-M group 9 
(24.5%), and other type(s) (3%) (SWEDRES 2011).  
 
In paper I we characterized a consecutive collection of all clinical ESBL-producing 
isolates referred to the Karolinska University hospital in 2005 (n=169). The Karolinska 
University hospital covers the majority of the population of Stockholm. The prevalence 
of ESBL was 0.7% among E. coli and K. pneumoniae in 2005 (I). We found that, as 
described above in more recent Swedish collections as well as in many other countries, 
CTX-M-15 was the dominating genotype followed by CTX-M-14 (I) (Fig. 6). The 
results were obtained with specific PCRs and subsequent DNA-sequencing, and only 
CTX-M-negative isolates were run with primers targeting TEM and SHV. Hence, it is 
possible that some of the CTX-M isolates harboured additional TEM and/or SHV-
genes (although not the opposite).  
 
 
 
Figure 6. Distribution of ESBL genotypes in Stockholm 2005 (modified from paper I). 
 
Apart from national data from SWEDRES, several other studies are supporting that 
CTX-M-15 is the most prevalent genotype in Sweden (Fang et al. 2004 and 2008, Cars 
et al. 2007, Lytsy et al. 2008, Onnberg et al. 2011, Tarnberg et al. 2013 , Helldal et al 
2013.). The largest study, by Tärnberg et al, showed a similar distribution of CTX-M 
enzymes in Linköping 2002-2007 as in our sudy (I) with 67% of 198 E. coli ESBL-
isolates belonging to group 1 and 28% to group 9. However, paper I was the first 
Swedish study of ESBL-genotypes based on a consecutive collection from a whole year 
in a non-outbreak situation. Epidemiological typing using pulsed-field gel 
electrophoresis (PFGE) showed that the collection was largely polyclonal, indicating 
that the spread in Stockholm occurred through horizontal gene-transfer by plasmid 
conjugation. Further, we found that the rate of E. coli isolates belonging to ST131 was 
41 % (I). Fig. 7 shows the clonal relatedness of the isolates and whether they were 
ST131-positive. In paper IV, which was a smaller study (n=61, E. coli n= 56), 29% of 
the isolates belonged to ST131. Seven of the 14 patients infected with an E. coli 
belonging to ST131 had travelled abroad within six months before their infection, 
suggesting that they might have picked up the EPE during the travel.  
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Figure 7. Clonal relatedness of clinical isolates of ESBL-producing E. coli referred to 
the Karolinska University Hospital in Stockholm in 2005. Isolates marked pabB belong 
to ST131 (paper I). Continued on next page. 
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Figure 7. Clonal relatedness of clinical isolates of ESBL-producing E. coli referred to 
the Karolinska University Hospital in Stockholm in 2005. Isolates marked pabB belong 
to ST131 (paper I). Continued from previous page. 
  11 
 
2.3 ESBLCARBA 
ESBLs that also inactivate carbapenems, so called carbapenemases or ESBLCARBA, 
pose an even greater threat than other ESBLs because they limit the treatment options 
further. As for other ESBLs ESBLCARBA is mainly produced by E. coli and K. 
pneumoniae. Most carbapenemases of clinical importance belong to KPC (K. 
pneumoniae carbapenemase), NDM (New Delhi metallo-!-lactamase, VIM (Verona 
integron-encoded ß-lactamase) or OXA-48 (oxacillinase). Their prevalence varies 
geographically. NDM is the most common enzyme in South-East Asia and the 
Middle East whereas KPC is dominating in Europe where OXA-48 is also 
increasingly reported. In Europe, the highest numbers of carbapenemase producing 
Enterobacteriaceae (CPE) are seen in Greece, Italy, Turkey and Israel followed by 
Spain, France and the UK. In the Nordic countries the rates are still very low (Canton 
et al. 2012). However, as displayed in Fig. 8, ESBLCARBA is increasing also in 
Sweden. 
 
 
 
Figure 8. Numbers and types of ESBLCARBA in Enterobacteriaceae in Sweden 2007-
2012 (SWEDRES 2012). 
 
Most cases have been associated with contact with health care in endemic countries 
such as Greece (KPC and VIM) and India (NDM). However, as for the CTX-M-
enzymes, spread of ESBLCARBA is becoming more frequently reported in the 
community. Thus, an increasing acquisition among travelers is to be expected in the 
future. Rapid identification of colonized or infected patients and screening of carriers 
is important to prevent an endemic scenario similar to that of the CTX-M-enzymes. 
To facilitate this work, reporting of ESBLCARBA became mandatory not only for 
laboratories but also for clinicians in Sweden in 2012. 
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3 TREATMENT ALTERNATIVES FOR EPE-
INFECTIONS 
3.1 THE DRUGS OF CHOICE: THE CARBAPENEMS 
ESBL inactivates most !-lactam antibiotics and co-resistance to quinolones, 
trimethoprim-sulfamethoxazole and aminoglycosides is frequently observed. When 
treating ESBL-infections, one must take into account not only the agents’ activity in 
vitro, but also the clinical activity against EPE specifically. The impact on the normal 
fecal flora and the association with selection of ESBL-producing strains should also be 
considered. Most EPE are susceptible to the carbapenems (Paterson and Bonomo 2005, 
Pitout and Laupland 2008, I). Meropenem, imipenem and doripenem have all shown 
excellent clinical effect against severe ESBL-infections (Chaubey et al. 2010), and 
ertapenem against UTI (Bazaz et al. 2010). Therefore, the carbapenems are considered 
the drugs of choice against ESBL-infection. However, EPE may develop resistance to 
the carbapenems due to loss of porins which reduces the permeability for the antibiotic 
(Doumith et al. 2009). In general EPE-isolates display lower MICs for meropenem and 
doripenem than imipenem and ertapenem. Resistance to ertapenem is more common 
than resistance to other carbapenems (Woodford et al. 2007). Meropenem and 
doripenem are therefore recommended for empirical treatment of severe EPE-
infection. However, there are several reasons to limit the use of the carbapenems: First, 
the use contributes to the selection of resistant strains in the gut (Falagas et al. 2013). 
Second, increasing rates of ESBLCARBA and other types of carbapenem resistance are 
being reported (Nordmann et al. 2009) and we need to “save it” for the most severe 
cases. Third, carbapenems are only administrated intravenously and not suitable for the 
treatment of non-severe infections. Thus, we need treatment alternatives, both for 
parenteral and oral use.  
 
There are several existing agents that have demonstrated high activity against EPE in 
vitro, although we lack data to support their clinical utility. Susceptibility data for EPE 
varies geographically and may also depend on the type of ESBL. In addition, the 
outcome of the susceptibility testing may be affected by the methods used in the 
laboratory, at least for certain agents (Pitout et al. 2008). In paper I, one of the specific 
aims was to evaluate possible treatment alternatives to the carbapenems in our setting. 
The susceptibility to a large number of oral and parenteral agents were tested against a 
consecutive collection of 169 EPE isolates collected in Stockholm during 2005. At the 
time, data on resistance-profiles for the various ESBL-genotypes were limited.  
However, there were indications that the CTX-M-15 had the most multi-resistant 
phenotype, which has later been confirmed (Pitout 2010, I). To learn more about this, 
susceptibility-rates were related to ESBL genotype. As expected, high resistance-levels 
were found for ciprofloxacin, trimethoprim and gentamicin among E. coli (28, 29 and 
53%). For K. pneumoniae we found high resistance to all antibiotics, although for E. 
coli we found several possible treatment alternatives both among parenteral and oral 
agents. Table 2 shows the agents for which we found the highest susceptibility rates for 
E. coli. The agents were compared to the carbapenems, here represented by ertapenem. 
Each of these agents is being discussed below. 
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Table 2. Antimicrobial susceptibility and ESBL genotypes, E. coli (paper I). 
 
Antimicrobial susceptibility* 
% susceptible isolates Genotype (No.) 
ERT TGC TZP TEM FOS NIT MEC 
blaCTX-M-14 (30) 100 
 
100 
 
100 
 
93 
 
97 94 
 
90 
 blaCTX-M-15 (108) 99 
 
100 
 
87 
 
70 
 
98 94 
 
89 
blaCTX-M-2 (2) 100 
 
100 
 
100 
 
100 
 
0 100 
 
100 
 blaSHV-5 (2) 100 
 
100 
 
100 
 
50 
 
100 100 
 
0 
 blaSHV-12 (7) 86 
 
100 
 
100 
 
43 
 
86 86 
 
57 
  
*ERT=ertapenem; TGC=tigecycline; TZP=piperacillin/tazobactam; TEM=temocillin; 
FOS=fosfomycin; NIT=nitrofurantoin; MEC=mecillinam 
 
 
3.2 !-LACTAM/!-LACTAMASE-INHIBITOR COMBINATIONS 
ESBLs can be inhibited in vitro by !-lactamase-inhibitors such as clavulanic acid and 
tazobactam, although their clinical activity have been questioned. Previously, ESBL-
producing isolates were reported resistant to all !-lactams and !-lactam/!-lactamase-
inhibitor combinations (!L/!LIs). However, the Clinical Laboratory Standards 
Institute (CLSI) and Europeean Committee for Antimicrobial Susceptibility Testing 
(EUCAST) have lowered the breakpoints, and now recommend reporting 
susceptibility results for !-lactam antibiotics as found, regardless of the presence of 
an extended-spectrum !-lactamase. The impact of these recommendations on 
susceptibility rates among EPE has not been fully studied. However, !L/!LIs have 
emerged as interesting alternatives to the carbapenems because of their high activity 
in vitro and low association with development of ESBL-infections (Vardakas et al. 
2012). Although comparative trials are limited, a recent review and meta-analysis by 
Vardakas et al, did not show inferiority to the carbapenems regarding mortality for 
empirical or definite treatment with !L/!LIs against BSI (Vardakas et al. 2012). A 
similar post-hoc analysis by Rodriguez-Bano et al. showed that amoxicillin/clavulanic 
acid and piperacillin/tazobactam were not associated with increased mortality 
compared to the carbapenems for the definite therapy of ESBL-E. coli BSI with origin 
in the urinary and biliary tract and susceptibility in vitro (Rodriguez-Bano et al. 2012). 
 
 
3.2.1 Piperacillin/tazobactam 
Apart from the studies of !L/!LIs against BSI mentioned above, current literature 
also supports the clinical action of piperacillin/tazobactam (TZP) for susceptible 
ESBL-producing isolates, at least in upper urinary tract infections (UTI) and 
pneumonia (Thomson and Moland 2001, Gavin et al. 2006, Rodriguez-Bano et al. 
2006, Peterson 2008). With the increasing frequency of ESBL calling for a reduction 
in the use of the cephalosporins, the use of TZP has increased substantially in 
Swedish hospitals the last few years. In paper I we found high susceptibility rates 
(87%) to TZP in accordance with several previous reports, although the lowest activity 
was seen among CTX-M-15 isolates. However, these numbers were determined with 
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gradient MIC-testing (Etest), a method that had not been evaluated specifically for 
ESBL-isolates. Failure to detect resistance to TZP had previously been reported using 
automated systems (Pitout 2008). Therefore, we aimed to evaluate the accuracy of the 
two commonly used diffusion-based susceptibility testing methods, gradient MIC-
testing (Etest) and disk diffusion. When determining MICs for TZP for the same 
isolates using Broth microdilution (BMD), which is considered the reference method, 
the susceptibility rate was only 58%. Thus, gradient MIC-testing was found to be 
unable to detect resistance to TZP in 56/169 cases. The discrepancies between Etest and 
broth microdilution are displayed in Fig. 9. 
 
 
Figure 9. Discrepancies between Etest and Broth microdilution for 
piperacillin/tazobactam (modified from paper I). 
 
Similar discrepancies were found when comparing susceptibility obtained with Disk 
diffusion and Broth microdilution (Fig. 10).  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 10. Broth microdilution vs Disk diffusion for piperacillin/tazobactam: discrepancies 
between MICs and zone diameters. The individual bars are coloured with the MICs of 
isolates having the various zone diameters. Several major errors occurred. Increasing 
the susceptibility breakpoint from 18 mm to 21 mm would, however, result in no 
major errors (modified from paper I).             
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When applying the old susceptibility breakpoint for disk diffusion ("18 mm), a number 
of isolates were classified as susceptible although they were actually resistant (Fig. 10). 
Since this phenomenon was not known before our publication (I), it is possible that 
previously described treatment failures with TZP against EPE could have been due to 
non-susceptible isolates. Thus, the clinical activity against susceptible isolates might be 
better than has been reported. On the other hand, susceptibility rates may actually be 
lower than previously described. These data shows the importance of calibrating the 
breakpoints against the reference method, and have resulted in a revision of the 
EUCAST disk diffusion breakpoint for TZP which is now "20 mm.                  
 
In general, resistance to TZP is increasing among Gram-negative pathogens. This has 
been associated with more pathogens expressing multiple !-lactamases 
simultaneously. Among these !-lactamases there has been an accumulation of 
mutations that decrease their susceptibility to inhibition by tazobactam (Sirot et al. 
1997, Shlaes 2013). Thus TZP is not the ultimate solution to the ESBL-problem, and 
more potent !L/!LIs are being evaluated. 
 
 
3.2.2 Cephalosporin/!-lactamase-inhibitor combinations 
Cephalosporins have traditionally been considered non-effective against EPE-
infection even with susceptibility in vitro (Paterson and Bonomo 2005). This problem 
has been shown to be related to the previously used higher cephalosporin breakpoints 
(Pitout 2010). In contrast to other EPE, CTX-M-producing strains sometimes present 
low MICs for ceftazidime (Pitout et al. 2005, I), and successful ceftazidime treatment 
in patients with CTX-M-producing E. coli featuring in vitro susceptibility has been 
described (Pitout and Laupland 2008). There are also reports indicating that high 
doses of cefepime could be effective (Lee et al. 2007). Although cephalosporins have 
been associated with the selection of ESBL-producing strains, they remain well 
tolerated, non-toxic, bactericidal antimicrobials, well suited for empirical treatment of 
severe infections. Although ESBLs usually lead to cephalosporin resistance, the 
cephalosporins resist hydrolysis by !-lactamases better than penicillins. This make 
cephalosporins easier to protect with !-lactamase-inhibitors (Shlaes 2013). Therefore, 
ceftazidime and other cephalosporins combined with new !-lactamase-inhibitors with 
broader spectrum than existing inhibitors, have emerged as promising treatment 
alternatives for EPE. One example of such new inhibitor is avibactam (NXL-104) that 
can inactivate KPC carbapenemases. Novel cephalosporins are also being developed 
and combined with old !-lactamase-inhibitors. 
 
 
3.2.3 Ceftolozane-tazobactam (CXA-201) 
The novel cephalosporin ceftolozane (former CXA-101) has a broad gram-negative 
spectrum with activity against carbapenem-resistant and cephalosporin-resistant 
Pseudomonas aeruginosa. Human phase 1 studies of CXA-101 have shown a 
favourable safety and predictable pharmacokinetic profile with high target attainment 
for infections in the urinary tract (Ge et al. 2010). Also, human phase 2 studies have 
been completed for CXA-101 against complicated urinary tract infection, and the 
microbiological and clinical outcomes were comparable to ceftazidime (Cubist, data 
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not published). However, ceftolozane can easily be hydrolysed by ESBLs and has 
therefore been combined with tazobactam. Ceftolozane/tazobactam (CXA-201) is 
being developed as a first-line intravenous therapy for the treatment of serious Gram-
negative infections caused by multi-resistant Enterobacteriaceae and P. aeruginosa, 
including EPE. In paper II, which was a collaboration with the pharmaceutical 
company Calixa Therapeutics (later acquired by Cubist Pharmaceuticals), we studied 
the in vitro activity of CXA-201 against our consecutive and largely polyclonal 
collection of 169 ESBL-producing strains. We found that the in vitro activity was very 
high, 88-98% depending on the concentration of tazobactam and the susceptibility 
breakpoint. The highest activity was seen with a high concentration of tazobactam 
(8mg/L) and the higher breakpoint (MICs were determined with broth microdilution) 
(Table 3). As previously described, the strain collection was relatively diverse 
according to PFGE (Fig. 7), and also comprised a similar fraction of CTX-M-15 and 
E. coli O25b-ST131 as reported from many other countries. Therefore we concluded 
that the results can probably be generalized to ESBL populations found in other 
regions of the world.  
 
 
Table 3. Activity of ceftolozane + tazobactam and comparators against EPE (paper II). 
Antimicrobial agent and concentration (breakpoint) % Susceptible isolates 
ceftolozane + tazobactam 4mg/L (1/4) 88 
ceftolozane + tazobactam 8mg/L (1/4) 96 
ceftolozane + tazobactam 4mg/L (2/4) 93 
ceftolozane + tazobactam 8mg/L (2/4) 98 
Ceftazidime + clavulanate 95 
Ceftazidime + tazobactam 93 
Piperacillin + tazobactam 58 
Amoxicillin + clavulanate 24 
Ampicillin + sulbactam 2 
     
As shown in Table 3, ceftolozane/tazobactam performed much better than other 
!L/!LIs on the market (TZP, amoxicillin/clavulanate and ampicillin/sulbactam), and 
could therefore be an interesting option for isolates resistant to TZP. However, high 
susceptibility rates were also obtained with new combinations of old agents, 
ceftazidime/clavulanate and ceftazidime/tazobactam. To a clinician, these alternatives 
might seem more convenient to introduce compared to developing new 
cephalosporins. However, new combinations of old agents need to undergo the same 
clinical trials as novel agents, but are not associated with the same profit, and are 
therefore not attractive to evaluate by the pharmaceutical companies. 
Although our study showed promising results for ceftolozane/tazobactam, other studies 
have now shown insufficient activity against ceftazidime-resistant Enterobacteriaceae 
and EPE populations in general with MIC90 of 16 and >16 (Sader 2012). 
Ceftolozane/tazobactam is currently undergoing Phase III trials for complicated UTI 
and complicated intraabdominal infection. Whether ceftolozane/tazobactam is actually 
a future therapeutic option against EPE infections, or just a better pseudomonas-agent 
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similar to ceftazidime when it comes to treating other Gram-negatives, remains to be 
seen. 
 
 
3.3 OTHER PARENTERAL AGENTS 
Apart from the carbapenems and !L/!LIs, there are several parenteral agents that 
have displayed high activity in vitro, but for which there is very little clinical data to 
support their effectiveness as empirical as well as definite treatment against EPE.  
 
Aminoglycosides (AGs) inhibit protein synthesis by binding to the 30S subunit of the 
ribosome, and!have good effect against Enterobacteriaceae, although the use is being 
limited by their nephrotoxic side-effects (Mingeot-Leclercq and Tulkens 1999). As 
mentioned before, co-resistance to AGs is frequent among CTX-M-15 producing 
Enterobacteriaceae through the plasmid-mediated aminoglycoside-modifying 
enzyme aac(6’)-Ib-cr (Oteo et al. 2010). Other aac(6’)-I-subclasses inactivate 
amikacin but not other AGs, but aac(6’)-Ib-cr causes partial cross-resistance between 
different AGs (Maurice et al. 2008, Hanberger et al. 2013). There are also several 
other mechanisms for AG-resistance, such as reduced transport trough the cell, 
methylation of RNA and increased activity of efflux-pumps of which the last affects 
the various AGs differently. Among ESBL-producing isolates, resistance to amikacin 
is less common than to gentamicin and tobramycin, which was also true for our 
isolates (x%vs Y%) (I). In Stockholm, gentamicin is the most commonly used AG, 
followed by netilmicin, while amikacin is mostly used against tuberculosis. This 
might have contributed to the high resistance to gentamicin. Generally, and also in 
our setting, amikacin is preferred for the treatment of ESBL-infection (Hanberger, et 
al. 2013) which is currently being acknowledged and implemented in the hospitals of 
Stockholm. 
 
In times of increasing antimicobial resistance, old and ”forgotten” agents are being 
re-evaluated. One example of an old antimicrobial that is being re-examined is 
temocillin. Temocillin is a ticarcillin derivate that (like other !-lactams) bind to 
penicillin-binding proteins and inhibit cell wall synthesis.!It acts only against 
Enterobacteriaceae (van Duin et al. 2013). Temocillin is only available in Belgium 
and the UK, where it has the indications BSI, UTI and lower respiratory tract 
infections. Temocillin has a high stability against various !-lactamases, including 
extended-spectrum TEM, SHV and CTX-M enzymes (Livermore and Tulkens 2009). 
With the increasing !-lactamases among Gram-negatives, this is being appreciated, 
and temocillin has been reported to retain good in vitro activity against EPE 
(Livermore et al. 2006). We found fairly high susceptibility rates in our collection of 
EPE (I) although lower than previous reports (Livermore et al. 2006) and somewhat 
lower for the most common ESBL genotype CTX-M-15 (70%). Considering that the 
clinical effect against EPE is not well studied, the susceptibility rate against CTX-M-
15-positive isolates may not be good enough to motivate an introduction of the agent 
on the Swedish market. However it might be an option to consider in the future, 
especially for pyelonephritis (Livermore and Tulkens 2009), where the effect is best 
shown for non-ESBL producing isolates. 
 
Tigecycline is a new tetracycline derivate (glycylcycline). Tigecycline is 
bacteriostatic and acts by binding to the 30S ribosomal subunit and inhibiting protein 
synthesis.!It is approved (in Sweden) for the treatment of!complicated 
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intraabdominal, soft-tissue- and skin-infections. Tigecycline has shown excellent in 
vitro activity against E. coli, including CTX-M-15 isolates (Pitout 2010, I), whereas 
Klebsiella spp. can easily develop resistance due to efflux (Garau 2008). Despite its 
high in vitro activity against EPE, tigecycline has limited urinary excretion and is 
therefore not suited for the treatment of UTIs (Kanj and Kanafani 2011) which 
constitute the majority of ESBL-infections. In its favor is the minor impact of 
tigecyclin on the normal human microflora (Rashid et al. 2012). However, the use of 
tigecycline has been associated with increased mortality in clinical studies (van Duin 
et al. 2013). This has been explained by insufficient antibacterial effect probably 
related to high intracellular accumulation and low serum concentrations. Tigecycline 
should therefore be used only when no other options are available.  
 
 
3.4 ORAL AGENTS 
With the rapid increase in community-acquired UTIs caused by EPE, the lack of 
available oral antimicrobial agents with activity against ESBL is a matter of concern. 
The high level of co-resistance to fluoroquinolones and trimethoprim has 
compromised these alternatives, and data on the clinical outcomes for other oral 
agents against ESBL-producing bacteria are scarce. As shown in Table 2 the E. coli-
isolates investigated in paper I retained high susceptibility to three oral agents: 
fosfomycin, nitrofurantoin and mecillinam. Nitrofurantoin and pivmecillinam 
constitute the two first-line therapies for uncomplicated lower UTI (cystitis) 
recommended by the Swedish National Health Institute (Infektionsläkarföreningen 
2006). The majority of the Swedish EPE-isolates display low MICs to both of these 
agents, and although data on their clinical efficacy against EPE isolates are lacking, 
we are using them against lower UTI also when caused by EPE. However, 
fosfomycin is considered the safest choice against cystitis caused by ESBL-producing 
E. coli and K. pneumoniae, regardless of ESBL genotype (Garau 2008, Falagas et al. 
2010).  
 
3.4.1 Fosfomycin 
Fosfomycin is a phosphonic acid derivative that is bactericidal against a broad 
spectrum of Gram-positive and Gram-negative organisms, by inhibiton of bacterial 
cell wall synthesis. Fosfomycin is currently available in many countries both in oral 
and intravenous forms. Oral fosfomycin should be restricted to treatment of lower 
UTI and has become first-line therapy for cystitis in several European countries with 
high prevalence of EPE (Falagas, Kastoris et al. 2010, Falagas, Vouloumanou et al. 
2010). Intravenous fosfomycin is used against more severe infections of various types 
(van Duin et al. 2013). Resistance to fosfomycin has previously been very low in E. 
coli, and related to chromosomal mutations. However, acquired resistance among 
CTX-M-15-producing ST131-isolates has been described and seems to be emerging. 
A Spanish study recently reported an increase in fosfomycin resistance in urin 
cultures with EPE from 0 to 14.4% between 2005 and 2011 (Rodriguez-Avial et al. 
2013). Fosfomycin was taken off the Swedish market in 2009 because of the low use. 
Ironically this happened just when we were entering the ESBL-era and the agent 
suddenly had a new important indication. A re-introduction would be welcome, since 
there are very few oral alternatives against ESBL-UTI. 
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3.4.2 Nitrofurantoin 
Nitrofurantoin is an antibiotic with low tissue distribution and high renal excretion, 
suitable for the treatment of lower UTI caused by E. coli. The effect is bacteriostatic 
at low and bactericidal at high concentrations.! Although clinical data on 
nitrofurantoin against EPE are far from extensive, the agent has been reported 
effective in the treatment of lower UTI (Tasbakan et al. 2012). In Sweden we still 
have very low resistance rates despite a tradition of relatively high use. However, 
with increasing resistance to trimethoprim, trimethoprim has lost its place in the first-
line therapy against lower UTI in favor of nitrofurantoin, and it remains to be seen 
how this will affect the resistance. In the mean time we are using it against lower UTI 
regardless of ESBL-production, because of high in vitro activity (I). In cases of 
treatment failure against EPE, pivmecillinam treatment may be an alternative. 
 
3.4.3 Pivmecillinam 
Pivmecillinam is an amidinopenicillin with selective and high activity against Gram-
negative organisms, especially E. coli. It is well documented that pivmecillinam is 
effective and well tolerated for the treatment of acute uncomplicated cystitis in 
women (Nicolle 2000) and long-term clinical experience from the Nordic countries 
supports its efficiency. As it is eliminated through the kidneys, very low 
concentrations are attained in feces and the impact on the fecal flora is therefore 
minor (Sullivan et al. 2001). However, pivmecillinam is not available in many 
countries outside Scandinavia. The in vitro activity of mecillinam is high against 
ESBL-producing isolates (I) and pivmecillinam could therefore represent a treatment 
alternative for lower UTI caused by EPE also in countries that traditionally have not 
had access to it. Apart from one case report suggesting that pivmecillinam could be 
effective against pyelonephritis caused by ESBL-producing E. coli (Nicolle and 
Mulvey 2007), there was no data on the clinical outcome for pivmecillinam against 
EPE before paper III. This paper was an attempt to evaluate the clinical and 
bacteriological activity of pivmecillinam against lower UTI caused by EPE further. 
The patients were selected from the cohort of patients with first time EPE-infection in 
paper IV (n=61). Patients with lower UTI that had received pivmecillinam as single-
therapy and whose urine isolates were retrievable (n=8) were included. The patients 
who had received other agents (n=9) were included as a control group. The study 
outcome was antimicrobial efficacy based on bacteriological and clinical cure. 
Bacteriologic cure was defined as <10
3
 CFU/ml at the 30 days follow-up. Patients 
were considered clinically cured if the urinary symptoms had resolved after 
completed treatment according to the medical record. Relapse of UTI was defined as 
symptoms of acute cystitis, and/or signs of upper UTI, presenting within 6 months 
after clinical cure. We found that all patients receiving pivmecillinam had good 
clinical response; however, the bacteriological cure rate was low (2/8). Interestingly, 
none of the patients with persisting bacteriuria after 30 days had a relapse of UTI 
within 6 months, whereas one of the patients with bacteriological cure did. The 
results are displayed in Table 4 (controls not shown). There was no indication that the 
received dose of pivmecillinam, in the range of 200 mg twice daily (b.i.d, i.e., bis in 
die, latin) to 200 mg three times daily (t.i.d, i.e., ter in die, latin), affected the clinical 
or the bacteriological outcome. However, none of the patients received 400 mg t.i.d..  
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The use of pivmecillinam is recommended as treatment for uncomplicated cystitis 
(Gupta et al. 2011), but not against complicated UTI. Half of the patients in our study 
could not be classified as uncomplicated as they had functional or structural 
abnormalities of the genitourinary tract (9/17 in total; 4/8 who received 
pivmecillinam). It is well known that patients with structural or anatomical problems 
within the urinary tract are less likely to experience bacterial eradication after 
infection. It is possible that the high rate of persisting bacteriuria in our collection to 
some extent reflects the underlying complicating factors of the patients, which could 
explain the low bacteriological cure. In these cases the selection of an antimicrobial 
for clinical therapy should be individualized considering patient tolerance, clinical 
presentation, recent prior antimicrobial treatment, prior urine culture results, and 
known or suspected susceptibilities, and we do not know if this was done. However, 
the importance of persisting bacteriuria can be questioned when clinical cure is 
achieved and relapse does not occur. Another fact to take into account in this small 
study is spontaneous cure of uncomplicated cystitis, which according to a Swedish 
clinical trial comparing pivmecillinam with placebo, may occur in about 20% of all 
patients (Ferry et al. 2007). However, this may only apply to the patients without 
underlying complicating factors and is therefore of less relevance in our study. 
Further, in the same study all pivmecillinam dosing regimens were superior to 
placebo. 
 
Although the number of patients in this series of case-reports is limited, our results 
give a clear indication that pivmecillinam has good clinical activity against lower UTI 
with EPE, but that the bacteriological activity is questionable, at least with the current 
dosage regimens in patients with underlying complicating factors. Potentially, this 
agent could also have a place in the antimicrobial armamentarium in countries where 
it has not previously been licensed. However, our data also suggest that persisting 
bacteriuria is of little clinical importance, although larger clinical studies are needed 
to confirm this. 
 
Large prospective comparative trials to evaluate the clinical activity of nitrofurantoin 
and pivmecillinam against EPE UTI are needed. These studies are difficult to perform 
in low-endemic countries like Sweden because of the very high number of patients 
that would have to be included in order to find enough patients with EPE. 
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Table  4. Women with cystitis: susceptibility and response to pivmecillinam treatment, and risk factors for ESBL (modified from paper III). 
 
Risk factors for ESBL infection 
Species  
(CTX-M-
group) 
Pivmecillinam 
dosage regimen
1 
Susceptibility 
(MIC mg/L/zone 
dia mm)
2
 
Bacteriological 
cure
4
 
Clinical 
cure 
Relapse 
of UTI 
within 6 
months 
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E. coli (CTX-
M-1) 
200mg t.i.d. 5d S (0.25 / 25) YES YES NO - - - - - Cambodia 
E. coli (CTX-
M-1) 
Data missing S (1 /18) NO YES NO AMX - - - - Italy 
E. coli (CTX-
M-9) 
200mg b.i.d. 7d, 
400mg bid 7d 
S (0.25 /28) NO YES NO - - Unknown 
agent 
(cystitis) 
YES Recurrent 
cystitis 
- 
E. coli (CTX-
M-9) 
200mg b.i.d. 7d S (0.5 /22) NO YES NO AMX - AMX, 
DOX 
- Inconti-
nence 
- 
E. coli (CTX-
M-1) 
200mg t.i.d. 7d S (2 / 17) NO YES NO - YES FLU, NIT - - - 
E. coli (CTX-
M-1) 
200mg t.i.d 7d S (0.25 /25) NO YES NO - YES Unknown 
agent 
YES MS, 
chronic 
catheter 
- 
E. coli (CTX-
M-8/25) 
200mg b.i.d. 7d S (0.25 / 26) NO YES NO - - - - - Spain 
K. 
pneumoniae 
(CTX-M-9) 
200mg b.i.d. 7d S (0.5 /23) YES YES YES 
(After 5 
weeks) 
- YES PcV - ESWL -08 - 
!
1B.i.d (bis in die, latin) = twice daily; t.i.d (ter in die, latin) = three times daily  
2 MIC-breakpoints according to EUCAST (zone diameter breakpoint) (S!/R>): MEC 8/8 (15/15) 
3 <1,000 CFU/mL, urine sample 1 month after initial culture 
4AMX=amoxicillin; DOX=doxycycline; FLU=flucloxacillin, PcV= fenoxymetyl penicillin, MZL=metronidazole 
5 within 6 months before infecti
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4 FECAL CARRIAGE OF ESBL-PRODUCING 
ENTEROBACTERIACEAE 
Fecal carriage of EPE among asymptomatic individuals is increasing. Colonizing 
bacteria may serve as a source for later infection, and therefore will affect the choices 
of empirical antimicrobial treatment. In order to limit the use of inappropriate empiric 
antimicrobial drug therapy, we need to define patients at risk for fecal carriage of 
EPE. Thereby we can limit the mortality in patients with severe infections caused by 
EPE. Also in non-severe infections it is critical to identify those with EPE-carriage in 
order to prevent and/or limit outbreaks. To address this need, prediction tools based 
on risk factors for EPE-infection are being created to identify patients harboring EPE 
organisms (Johnson et al. 2013). In this context it is not only important to define 
patients at risk for carriage of EPE but also to predict how long the ESBL-carriage 
will persist and identify patients at risk for prolonged carriage. Very little is known 
about the duration of ESBL-carriage as well as host and pathogen factors associated 
with prolonged carriage. These aspects of EPE-carriage were studied in paper IV.  
 
 
4.1 THE NORMAL FECAL FLORA 
The human colon contains 10
12 
bacteria per gram of contents and >100 bacterial 
species. Major functions of these bacteria are metabolic activities that result in 
salvage of energy and absorbable nutrients, trophic effects on the intestinal epithelia 
and protection against potentially pathogenic microorganisms (Guarner and 
Malagelada 2003). The gut flora prevents the colonization of exogenously introduced 
organisms but also avoid the overgrowth of already present pathogens such as certain 
strains of E. coli. There are several mechanisms that may contribute to inhibition of 
pathogens, e.g. prevention of access to adherence sites in the mucosa, production of 
inhibitory substances or conditions and reduction of nutrients. The specific bacteria 
that are the most important in this defense are not known, although studies have 
suggested that obligate anaerobes are crucial (Donskey 2004).  
 
 
4.1.1 Escherichia coli 
E. coli is the most prevalent facultative aerobe in the feces of humans (Donskey 2004). 
Most strains do not cause disease. However, E. coli is also an important pathogen, 
being the most common cause of UTI. E. coli may also cause abdominal, airway, 
wound and blood stream infection as well as diarrhoea and meningitis. Uropathogenic 
strains of E. coli express certain properties, products or structures referred to as 
virulence factors (VFs). VFs help the organism to overcome host defences and colonize 
or invade the urinary tract. VFs associated with UTI include adhesins (P fimbriae and 
type 1 fimbriae), the aerobactin system, hemolysin, K capsule and resistance to serum 
killing (O-antigen) (Johnson 1991). Fig. 11 shows how these VFs can interact with a 
host cell to cause infection and Table 5 lists their main functions. 
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Figure 11.  Schematic overview of an E. coli interacting with a host cell. Attachment is 
the first necessary step in the colonization of a host’s mucosal surfaces and is facilitated 
by fimbriae that also stimulate inflammation. The exotoxins secreted by the bacterium 
facilitate invasion. The K-antigen helps the bacteria to avoid phagocytosis by the 
immune-system and helps the O-antigen promote serum resistance and avoid lysis. 
(Most of the picture adapted from Johnson 1991). 
 
 
Table 5. Major VFs of uropathogenic strains of E. coli and their functions 
 
Virulence factor Effect*  
P-fimbriae Adhesion to host tissue 
Stimulates inflammation 
Type-1-fimbriae Adhesion to the mucosa 
Renal scarring 
Aerobactin Promotes bacterial growth  
Hemolysin Toxicity to host tissue 
Disruption of phagocytosis 
Release of iron from erythrocytes 
K-antigen Avoidance of phagocytosis 
Promotes serum resistance 
O-antigen Promotes serum resistance 
* (Johnson 1991)  
 
In the clinical microbiological laboratory, all E. coli share the same features of the 
species, although they may express different virulence factors. Unless these factors are 
looked for by molecular methods, one will not be able to distinguish between 
pathogenic and non-pathogenic E. coli.  
 
E. coli can be divided into six phylogenetic groups (A-E) and/or be classified by 
serotype, based on differences in their O (lipopolysaccharide), H (flagellar protein), and 
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K (capsula) antigens. Although these classification systems cannot predict virulence, 
phylogroups B2 and D have been associated with high virulence (Wold, Caugant et al. 
1992). Strains within the same serotypes and/or phylogroups can be distinguished by 
genomics. 
 
 
4.1.2 Klebsiella pneumoniae 
K. pneumoniae is an encapsulated and non-motile bacteria. It is the clinically most 
significant of the Klebsiella spp. and infections occur in humans of all ages although 
the highest risk groups appear to be infants, the elderly and the immunocompromised. 
K. pneumoniae is associated with hospital acquired infections such as catheter related 
UTI and ventilator associated pneumonia (VAP) but is also the second causative agent 
of UTI in the elderly. K. pneumoniae express O-antigens and K-antigens on their 
surface which, as for E. coli, contribute to pathogenicity and form the base for 
serogrouping. Serogruping or screening for virulence genes was not performed within 
this thesis (Schaechter 1993, Mandell 2000). 
 
 
4.2 PREVALENCE AND RISK FACTORS FOR EPE-CARRIAGE 
We know that asymptomatic fecal carriage of EPE is increasing rapidly but it is very 
difficult to estimate how wide-spread carriage of EPE is in entire populations. 
However, there is a number of reports on the prevalence rates of fecal ESBL-carriage 
from different parts of the world. Asymptomatic carriage among healthy individuals 
has been reported as 65.7% from Thailand (Luvsansharav et al. 2012) and 6.7% from 
Spain (Oteo 2010). In a study from the Netherlands of community patients with 
gastrointestinal complaints 10.1% were ESBL-positive (Reuland et al. 2013). A British 
study by Wickramasinghe et al showed a point prevalence rate of 11.3% in fecal 
samples from community patients, and that the prevalence was significantly higher 
(22.8%) in patients with an origin in South Asia or the Middle-East (Wickramasinghe 
et al. 2012). In children attending a pediatric ward in Guinea Bissau the prevalence was 
32.6% (Isendahl et al. 2012). There are also a few Swedish studies reporting an EPE-
prevalence in feces of 3% of primary care patients and 7% among hospitalized patients 
in Skåne (Stromdahl et al. 2011), and 5% in patients admitted for abdominal surgery 
in Linköping 2006-2007 (Chabok et al. 2010). In healthy pre-school children in 
Uppsala 2.9% were ESBL-positive (Kaarme et al. 2013) and so were 3% of residents 
of nursing homes in Stockholm (Andersson et al. 2012).  
 
Some parts of the world are considered high-risk areas, and travel to these areas such as 
the Indian subcontinent and the Middle East, is a major risk factor for acquisition of 
asymptomatic fecal carriage of EPE (Tangden et al. 2010, van der Bij and Pitout 2012). 
As discussed previously, the high acquisition among travellers is largely linked to the 
internationally spread E. coli clone ST131, carriage which may occur through 
consumption of contaminated food and water (Peirano and Pitout 2010). In endemic 
regions previous healthcare contact and antimicrobial exposure have been identified as 
risk factors for asymptomatic carriage (Luvsansharav et al. 2012). Contact with 
healthcare centres and previous use of antimicrobial agents including cephalosporins 
and fluoroquinolones as well as comorbidities (renal and liver pathology, diabetes 
mellitus) are also well known risk factors for community-onset infections with EPE 
(Ben-Ami et al. 2009, Oteo et al. 2010). The spread within hospitals is facilitated if the 
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EPE-carrying patient has diarrhoea, urinary catheter or other type of catheters and 
drains and of course low infection control standards. However, with the increasing 
number of EPE-carriers, transmission of EPE within households has been found to 
outweigh nosocomial dissemination in the non-outbreak setting (Hilty et al. 2012).  
 
 
4.3 DURATION OF CARRIAGE 
Although the prevalence and risk factors for fecal carriage with EPE have been studied, 
little is known about the time course of stool colonization of EPE. One study from 
Thailand shows that the fecal carriage often persists for at least three months and that 
antibiotic treatment may prolong the carriage (Apisarnthanarak et al. 2008) and results 
from a Slovenian study indicates that 51.5% were carriers after six months (Papst L. 
2012). Warren et al. found 20% of the patients to be carriers one year after infection, 
but less than 5% after two years (Warren et al. 2008). In a smaller Swedish study 
10/41(24%) patients (24%) carried EPE after 3-8 months (Tham et al. 2012). A recent 
Israeli study of the duration of carbapenem resistant Enterobacteriaceae (CRE) showed 
that mean time to CRE negativity was 387 days (95% confidence interval: 312-463). 
Seventy-eight percent of patients (64/82) had positive culture at 3 months, 65% 
(38/58) at 6 months, and 39% (12/30) at 12 months (Zimmerman et al. 2013). In a 
Norwegian study of infants colonized during a nosocomial neonatal intensive care 
unit outbreak and their household contacts, the median carriage time among the 
infants was 12.5 months, although only 2.5 months among their parents (Lohr et al. 
2013). A possible explanation for this is that the fetal intestine is sterile and that 
colonizing bacteria during the first days of life influences the composition of the 
intestinal flora (Westerbeek, van den Berg et al. 2006) and leads to persistence of the 
colonizing bacteria. Paper IV, which presents prospective data on the duration of fecal 
carriage of ESBL after first time infection caused by an EPE (n=61), showed that 66% 
were carriers after three, 55% after six and 44% after twelve months. The main 
limitation of this study is the fairly small number of patients. However, the mean age, 
sex and culture material did not differ from the total group of patients diagnosed with 
clinical ESBL-infection during recruitment (n=522) as shown in Table 6, indicating 
that the results should be generalizable and relevant for most patients with ESBL-
infection.  
In accordance with previous studies (Alsterlund et al. 2012, Lohr et al. 2013) we found 
that among EPE-carriers twelve months after EPE-infection it is not uncommon with 
one or several negative fecal samples within the first year of carriage (IV, ref). It is 
possible that EPE persists in the gut but is suppressed by the normal intestinal flora 
enough not to be detected by routine methods, and that ecological disturbances caused 
by e.g. antimicrobial treatment on a later occasion promotes overgrowth of the resistant 
bacteria. However, in our material (IV) there was no correlation between antibiotic 
intake at any stage of the follow-up and a shift from negative to positive faecal samples. 
Three consecutive negative samples have previously been suggested to define 
elimination of carriage (Alsterlund et al. 2012), although our data indicates that three 
samples may be too few.  
 
 
  26 
Table 6. Characteristics of 508 patients with EPE detected at the clinical microbiology 
laboratory at Karolinska University Hospital between February and December 2009
1
 
(paper IV). 
 
 
All 
patients 
(n=508)
 
Patients 
included in 
analyses 
(n=61)
 
Patients not 
included in 
analyses 
(n=447)
 
P-value
 
Female
 
337 (66)
 
38 (61)
 
299 (67)
 
0.48
 
Age  (mean)
 
57.8
 
58.3
 
57.7
 
0.87
 
Level of care
    
0.002
 
Hospital 
inpatients
 
308 (60)
 
35 (57)
 
273 (61)
  
Hospital 
outpatients
 
50 (10)
 
14 (23)
 
36 (8)
  
Long term care 
facilities
 
25 (5)
 
0
 
25 (6)
  
Primary care
 
125 (25)
 
12 (20)
 
113 (25)
  
Culture material
    
0.39
 
Urine
 
437 (86)
 
51 (84)
 
386 (86)
  
Blood
 
24 (5)
 
5 (8)
 
19 (4)
  
Other
 
47 (9)
 
5 (8)
 
42 (9)
  
 
1
Data presented as number and column percentage in parenthesis if not otherwise 
stated. 
 
 
4.3.1 Factors affecting the duration of carriage 
Very little is known about how host and pathogen factors affect the duration of carriage 
of EPE. Previous studies have suggested that antimicrobial treatment will prolong 
carriage (Apisarnthanarak et al. 2008, Lohr et al. 2013), and studies of CRE has shown 
that multiple hospitalizations and CRE disease (as opposed to screening samples) 
extend the duration of carriage (Schechner et al. 2011, Zimmerman et al. 2013). 
Abnormalities within the urinary tract have also been associated with persisting 
carriage of KPC K. pneumoniae (Feldman et al. 2013). In infants, apart from 
antimicrobial treatment, caesarean section has been found to prolong carriage of EPE 
(Lohr et al. 2013). Caesarean section is known to influence the development of the 
intestinal microbiota (Westerbeek et al. 2006), which could explain the association. 
We found strain factors related to high virulence to be associated with persisting 
carriage of EPE, whereas antimicrobial treatment and other patient-related factors were 
not (Table 7) (IV). These findings are being discussed further below. 
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Table 7. Comparison of patient and strain factors between ESBL-carriers and non-
carriers twelve months after EPE-infection (modified from paper IV). 
 
 
1 
Bold face=P<0.05. 
 
2 
Six months before ESBL-infection 
3 
For the original infection with ESBL-producing bacteria (not additional treatment 
during follow-up) 
4 
CIP=ciprofloxacin, TMP=trimethoprim, TSU=trimethoprim-sulfamethoxazole, 
NIT=nitrofurantoin, MEC=mecillinam                
 
 
 
 
 
 
 
Variable 
  
Carriers 
at 12 
months 
n(%) 
Non-carriers at 12 
months n(%) 
P-value 
Women  14 (54) 21 (60) 0.8 
S
ex
 
an
d
 
ag
e 
Median age 
(years) 
63 60 0.9 
Urinary tract 
infection 
24 (92) 30 (86) 0.7 
T
y
p
e 
o
f 
in
fe
ct
io
n
 
Blood stream 
infection
1
  
6 (23) 1 (3) 0.04 
Previous 
antimicrobial
2
 
10 (42) 16 (47) 0.8 
Hospital stay
2
 13 (52) 14 (41) 0.4 
Travel abroad
2
 11 (31) 20 (60) 0.3 
 R
is
k
 f
ac
to
rs
 
fo
r 
ac
q
u
is
it
io
n
 
o
f 
E
P
E
 
Abnormalities 
urinary tract  
5 (20) 8 (24) 0.76 
Carbapenem 
treatment 
5 (19) 2 (3) 0.15 
CIP + TMP 
+TSU
4 
9 (39) 11 (52) 0.8 
NIT + MEC
4
 7 (30) 11 (52) 1.0 
>2 antimicrobial 
agents  
3 (13) 5 (16) 1.0 
A
n
ti
m
ic
ro
b
ia
l 
tr
ea
tm
en
t3
 
>3 antimicrobial 
agents  
2 (9) 2 (6) 1.0 
Phylogroup B2 12 (52) 6 (23) 0.04 
ST131 9 (39) 5 (19) 0.2 
CTX-M-1-group 15 (60) 23 (74) 0.4 
CTX-M-9-group 10 (40) 3 (10) 0.01 
fim  23 (100) 25 (96) 1 
S
tr
ai
n
 f
ac
to
rs
 
pap 14 (7) 3 (12) 0.7 
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4.3.1.1 The virulence of the bacteria 
E. coli strains differ widely in colonization capacity in the colon, and this capacity is 
linked to virulence factors in extraintestinal infection (Wold et al. 1992). Strains 
belonging to the phylogenetic group B2 and D have an enhanced ability to persist in the 
intestinal flora (Wold et al. 1992). Genes encoding P fimbriae and other virulence 
factors associated with uropathogenicity such as type 1 fimbriae, hemolysin, capsular 
polysaccharides and aerobactin are enriched in resident strains, and there seems to be 
an additive effect of these factors promoting persistence (Wold et al. 1992, Melican et 
al. 2011, Ostblom et al. 2011). In accordance with previous studies on non-ESBL 
isolates, we found that the E. coli phylogenetic group B2 was associated with 
prolonged carriage of EPE, which was also the case for CTX-M-gr.-9 (IV). Of the 
eleven CTX-M-gr.-9-positive E. coli isolates, nine belonged to phylogroup B2 or D (4 
and 5 isolates respectively) indicating that these strains were highly virulent. Although 
B2 is strongly associated with high virulence, we did not find any differences in the 
presence of the pap- and fim-genes encoding the uropathogenetic virulence factors p-
fimbriae (pap, pili associated with pyelonephritis) and type 1-fimbriae (fim) between 
carriers and non-carriers. On the contrary, almost all infectious isolates were positive 
for fimH and fimAMT78-genes, probably reflecting the fact that infectious isolates of E. 
coliare virulent and mostly uropathogenic by definition. Our findings still indicate that 
strain virulence could be an important factor also for persistence of ESBL-producing E. 
coli in the intestinal microbiota. 
 
We also found that CTX-M-gr.-9 was correlated to prolonged carriage. This ESBL 
genotype is perceived to be associated with less virulent strains than CTX-M-gr.-1.  
CTX-M-gr.-1 includes the CTX-M-15 enzyme associated with the highly virulent 
international clone ST131 and indirectly to phylogroup B2. Previous studies 
demonstrate that virulence of E. coli ST131 is related with the strain and not with the 
presence of blaCTX-M-15 (Rogers et al. 2011). Of the 11 CTX-M-gr.-9 E. coli isolates 9 
belonged to phylogroup B2 or D (4 vs. 5 isolates), indicating that these strains were 
highly virulent which might explain the association with prolonged carriage.  
 
4.3.1.2 Antimicrobial treatment 
Antimicrobial treatment may suppress the commensal bacteria and facilitate for 
colonizers and pathogens to find an ecological niche. There is a wide variability in the 
ecological effect of antimicrobial agents. The factors of most importance for ecological 
disturbances are the antibacterial spectrum, degree of absorption, route of elimination, 
enzymatic inactivation and/or binding to human fluids and intestinal material (Sullivan 
et al. 2001). For example, trimethoprim-sulfamethoxazole and ciprofloxacin, show high 
concentrations attained in faeces and an important effect on the intestinal flora, while 
pivmecillinam and nitrofurantoin, agents that are mainly eliminated through the 
kidneys, are considered to account for minor impact (Sullivan et al. 2001). The 
carbapenems have the broadest spectrum of the antibiotics discussed in this thesis, and 
are therefore associated with considerable ecological disturbances. 
 
It is possible that the use of antimicrobial agent(s) did affect the duration of carriage 
noted in paper IV. However, we did not find that the number of received antimicrobial 
agents was correlated to the duration of carriage and neither were there any differences 
between carriers and non-carriers at 12 months for specific agents. There was a trend 
that treatment with carbapenems was more frequent in patients with prolonged carriage 
(19% vs. 3%), although the difference was not statistically significant (p-value: 0.15). 
The use of carbapenems is associated with BSI, which was associated with prolonged 
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carriage in univariate analysis although not in multivariate analysis. However, E. coli 
strains belonging to the virulent phylogroup B2, were more common among patients 
with BSI. Thus, an association between BSI and/or carbapenem use and persisting 
carriage (although not shown in our study) could actually be an effect of strain 
virulence. Larger studies are needed that assess the effects of usage of different 
antibiotic classes on carriage duration. These should also take into account possible 
confounding factors since it is likely that antibiotic usage is associated with host factors 
such as co-morbidities.  
 
4.3.1.3 Patient factors 
Underlying abnormalities within the urinary tract are well known risk factors for 
acquisition of ESBL (Oteo et al. 2010), and have also been associated with persisting 
carriage of KPC K. pneumoniae (Feldman et al. 2013), but were in our study not 
associated with persisting carriage (IV). However, 6/13 (46%) patients with underlying 
conditions of the urinary tract did get a new ESBL-infection during follow-up 
compared to the overall rate 19/61 (31%). This could possibly be an effect of more 
complicated, persisting and/or frequent urinary tract infections, more frequent hospital 
stays and exposure to antimicrobials. Carbapenem treatment was also overrepresented 
among these patients (3/13 (23%) vs 6/61 (10%)), which might be an effect of more 
severe infection or more resistant strains due to previous antibiotics. 
 
 
4.4 THE HOST STRAIN DURING EPE-CARRIAGE 
4.4.1 Clonality and strain diversity 
Subsequent generations of bacteria retain the parental DNA pattern until the DNA 
changes, which is known as clonality. Changes in the DNA through insertions, 
deletions and rearrangements lead to strain diversity. Within a clone, minor changes in 
the DNA (genetic events) over time are expected. There are various methods to 
determine whether different bacterial isolates are clonally related or diverse 
(epidemiological typing). In our studies epidemiological typing was performed with 
PFGE. PFGE is a high resolution method based on restriction enzymes cutting the 
entire bacterial DNA into various sized fragments. Changes in the DNA change the 
relative position of the restriction sites and thus change the length of the DNA 
fragments, which will be interpreted as strain diversity. However, when comparing 
isolates over time, as in paper IV, we cannot expect the PFGE-patterns of isolates 
belonging to the same strain to be indistinguishable when several or many months have 
passed. Some differences must be allowed.  
 
Because ESBL-genes are transferable between bacteria it is likely that ESBL-enzymes, 
during fecal carriage, are transferred from colonizing strains to strains belonging to the 
normal intestinal microbiota. Therefore, in paper IV, PFGE was performed to 
determine whether the ESBL-production was found in the same or new strains for each 
patient during follow-up. We found the ESBL-production in another species and/or in a 
different or additional strain of E. coli or K. pneumoniae than in the beginning of the 
study in 28% of the patients (Fig. 12).  
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Figure 12. ESBL-producing strains during carriage. Overview of the duration and 
dynamics of fecal carriage. Fig. 12A displays results of cultures and PFGE for those 
who were carriers at 12 months, Fig. 12B for non-carriers. Each row shows the results 
for one patient. The symbols represent the species and strains where ESBL was found 
in the clinical sample and in feces at 1, 3, 6 and 12 months (paper IV). 
 
 
This finding was more frequent among carriers at twelve months than non-carriers, 
supporting the hypothesis that persisting carriage is linked to transfer of ESBL-genes 
from infecting or colonizing strains to the normal fecal flora. However, nine of these 
patients had a new CTX-M-group in one or several of the follow-up samples, showing 
that the ESBL-production in these strains was not caused by the same ESBL-gene as in 
previous samples. The most probable explanation is that some of these patients were 
colonized with several strains in the beginning of the study, but that all the strains were 
either not present in all fecal samples or that we were unable to distinguish these as 
different strains when selecting colonies from the screening plates. Further, it cannot be 
excluded that some of these patients had acquired a new EPE isolate during the follow-
up. Since there is little Swedish data on the prevalence of fecal carriage of ESBL in the 
community, it is very difficult to calculate the risk of being re-colonized. However, 
with the low prevalence of ESBL among clinical isolates of E. coli and K. pneumoniae 
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(<3%) (Struwe and Olsson-Liljequist 2009, Chabok et al. 2010, Stromdahl et al. 2011, 
Andersson et al. 2012) we find this less likely, provided that there had been no new 
exposure to risk factors such as hospital stay or travel to a high-risk country.  
 
4.4.2 Plasmid transfer of ESBL-genes between different strains 
ESBL-genes are often located on conjugative plasmids belonging to the IncF group, 
especially IncFII, as well as I1, N, and K, with high potential of recombination. A/C, H, 
L/M and P have also been found (Novais et al. 2007, Coque et al. 2008, Chouchani et 
al. 2012, Carattoli 2013). Our hypothesis was that during carriage of EPE, the plasmid 
harbouring the ESBL-gene is transferred from the colonizing strain to strains in the 
normal fecal flora. To study whether an ESBL-gene has been transferred through 
plasmid conjugation one needs to characterize the plasmids in each strain. One way to 
characterize plasmids is by grouping them into incompatibility (Inc) groups (Datta and 
Hedges 1971). To determine the Inc groups of the plasmids in the samples we used 
PCR-based plasmid replicon typing described by Carratolli et al, detecting the 18 major 
plasmid families for Enterobacteriaceae (Carattoli et al. 2005). In accordance with 
previous reports on EPE (Coque et al. 2008) we found that plasmids belonging to the 
IncF group were commonly detected in our isolates (FrepB (n=46), FIA (n= 29) and 
FIB (n=27)). These plasmids are frequently present in both ESBL- and non-ESBL-
producing E. coli and K. pneumoniae, so their presence in two different ESBL-
producing strains from the same patient does not confirm that an IncF plasmid 
transferred the ESBL gene. Further, it is quite common for isolates to have several 
plasmids, and one plasmid may contain multiple replicons. In this material FrepB, FIA 
and FIB were the most common replicon contents, and for the patients with ESBL-
production in a different strain and/or species we found that in 4/17 cases the replicon 
content of the first and at least one of the new strains were identical. The results of the 
plasmid characterization are shown in Fig. 13. 
 
We have not conducted experiments to confirm that ESBL was linked to the specific 
plasmids, and therefore have not specifically studied the replicon type of the plasmid 
carrying ESBL. The ESBL-containing plasmid could be of another replicon type than 
the one detected, although it is probable that they were associated. However, if two 
strains from the same patient carry plasmids with completely different Inc groups we 
can conclude that there has not been a plasmid transfer within the fecal flora of the 
patient, thus the new strain must have come from a different source. To confirm that the 
plasmids actually carry the ESBL-genes plasmid conjugation experiments would have 
to be performed. To confirm that two different plasmids carry the same DNA sequence 
that encodes the ESBL-production, restriction fragment length polymorphism (RFLP) 
could be used. To further characterize the plasmids carrying the ESBL-genes in our 
collection of strains, a collaboration with researchers at the Swedish Institute for 
Communicable Disease Control has been initiated.
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Infecting
Patient isolate(s) 1 month 3 months 6 months 12 months
1       FrepB       -       FIA, FIB, I1, FrepB       FIA, FIB, FrepB       FIA, FIB, FrepB
2       FIA, FIB       FIA, FIB       FIA, FIB       FIA, FIB      FIA, FIB
4       FIB, FrepB       FIB, FrepB          -       FIA, FIB, FrepB          FIA, FIB, FrepB         -       FIA, FIB, FrepB         FIA, FIB, FrepB       FIA, FrepB
8       FIA, FIB, FrepB       FIB, FrepB       FIA, FIB, FrepB          FIA, FIB, FrepB       FrepB       FIB, FrepB
10       FrepB       FIA, FrepB       FIA, FrepB       FIA, FrepB       FIA, FrepB         FIB, I1, FrepB
18       FIA, FrepB       FIA, FrepB          F1A, FIB, FrepB       FIA, FrepB          FIA, FIB, FrepB       FIA, FIB, FrepB       FIA, FrepB
19       FIA, FrepB       FIA, FrepB ns       FIA, FrepB          FIB, I1, FrepB       FIB, I1
21       FIB, FrepB       FIB, FrepB          FIA       -       -       FIB
22       FrepB       I1, FrepB ns       I1
23       FIB, FrepB       FIA, FIB, FrepB       FIB, FrepB
26       -       FIA, FrepB      FIA, I1         FrepB                    FIA, FIB, I1, FrepB        -
32       FIA, FIB       FIA, FIB       FIA, FIB, FrepB
33       -       FIB, FrepB          FrepB       FrepB       -
42       FrepB         FIA       FrepB         FIA, FIB              -          FIA, FIB, FrepB         FIA, FIB, FrepB       FIA, FIB, FrepB
44       FIA, FIB, HI1, I1       FIB, I1       FIA, FIB, FrepB
49       FIB, FrepB       FrepB          -       FIA, FIB, FrepB       FIA, FIB, FrepB
52       FIA, FIB, FrepB       FIB, FrepB          -       FIA, FIB, FrepB       FIA, FIB, FrepB
       E. coli, first strain, CTX-M-1        E. coli, third strain, CTX-M-1
       E. coli, first strain, CTX-M-9        E. coli, fourth strain, CTX-M-9
       E. coli, first strain, ESBL-phenotype, no confirmed genotype        E. coli, fifth strain, CTX-M-9
       E. coli, second strain, CTX-M-1        K. pneumoniae, first strain, CTX-M-1
       E. coli, second strain, CTX-M-9        K. pneumoniae, first strain, CTX-M-9
       E. coli, second strain, TEM        K .pneumoniae, second strain, CTX-M-1
       E. coli, second strain, ESBL-phenotype, no confirmed genotype        No PFGE- or CTX-M-typing result
Fecal isolates
Patients with ESBL-production detected in a new species and/or an additional strain during follow-up
!!
!!!!!!!!!!!!!!!!!!!!
 
 
 
Figure 13. CTX-M-groups and replicon contents of ESBL-producing isolates from patients with ESBL-production detected in a new species or strain 
during carriage. Each row shows the results of cultures, PFGE and PBRT for one patient. The symbols represent the species and strains where ESBL was 
found in the clinical sample and in feces at 1, 3, 6 and 12 months (paper IV).
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5 CONCLUSIONS 
The papers included in this thesis provide insights on the epidemiology of ESBLs in 
Stockholm, knowledge on treatment alternatives to the carbapenems as well as on the 
duration of carriage of EPE. More specifically we show that:  
 
• blaCTX-M-15 is the most common ESBL genotype in Stockholm. 
 
• There are several therapeutic parenteral and oral alternatives to the carbapenems 
available for E. coli but few for K. pneumoniae. 
 
• Ceftolozane-tazobactam has good in vitro activity against ESBL-producing 
Enterobacteriaceae and may be a future therapeutic option for infections caused 
by TZP- and ACL-resistant isolates. 
 
• Pivmecillinam seems to have good clinical activity against lower UTI caused by 
ESBL-producing Enterobacteriaceae although bacteriological cure rates are 
low. The persisting bacteriuria seems to be of little importance. 
 
• Disk diffusion and Etest can accurately predict susceptibility to CTX and CAZ 
among ESBL-producing isolates, but not to TZP with the breakpoints used at 
the time of the study. 
 
• Fecal carriage often persists one year after infection, and prolonged carriage is 
associated with E. coli phylogroup B2 and CTX-M-group 9.  
 
• The host strain of ESBL-production frequently changes throughout the carriage 
and persisting carriage may also be linked to the transfer of plasmids carrying 
ESBL-genes from an infecting or colonizing strain to the normal fecal flora.  
 
• Negative samples within the first year do not necessarily imply elimination of 
carriage. 
 
This knowledge will hopefully contribute to providing better medical care of patients 
with ESBL-infection. It may also prove important for defining patients that require 
prolonged isolation in single rooms or cohorts. Thereby the spread of ESBL-producing 
bacteria in hospitals and long term care facilities can be limited. In the future, 
comparative trials are needed to further evaluate the clinical effect of antimicrobial 
agents against EPE-infection to make sure that we provide the best treatment available 
for the patients. Larger prospective studies that assess strain virulence, the effects of 
usage of different antibiotic classes as well as host factors such as co-morbidities on the 
duration of fecal carriage of ESBL are also needed. With the rapid increase in EPE-
carriage these types of studies could soon be feasible also in Sweden.  
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